Penny stocks those stocks that trade for low prices, often with share prices of less than a dollar per share are dangerous. Period. Indeed, with a few exceptions, investors should steer clear of these uber-cheap stocks, which typically trade over-the-counter and not on a major exchange.
Call them penny stocks, microcaps or OTC stocks; by any name, theyre bad news. Promises of quick and easy riches are easier to fall for when an investment can be made with so little money up front. An investor might think, “How risky could it be?”
Plenty. Per the Securities and Exchange Commission: Academic studies find that OTC stocks tend to be highly illiquid; are frequent targets of alleged market manipulation; generate negative and volatile investment returns on average; and rarely grow into a large company or transition to listing on a stock exchange.
Top 5 Low Price Stocks To Own Right Now: Amgen Inc.(AMGN)
- [By ]
All three are market-cap weighted — that is, the larger the company is, the more it impacts the overall performance of the index/fund. In the Nasdaq, for instance, the impact of any move in Apple, Microsoft or Amazon — which are weighted 12%, nearly 9% and nearly 8%, respectively — would be much more significant than the index impact of a much smaller position such as Amgen (Nasdaq: AMGN), with less than 2% of the index assets allocated.
- [By Tom Gentile]
After the Senate scored the votes on Tuesday to review a plan for repealing or repealing and replacing what’s come to be known as Obamacare, we saw a mixed-bag reaction from healthcare stocks. Even some of the bulletproof ones, like Amgen Inc. (Nasdaq: AMGN), closed lower from their opening highs.
- [By Johanna Bennett]
Shares of Amgen (AMGN) led the drop in the S&P 500 today falling almost 6.4% to close at $168.61 after the drug maker unveiledlong-awaited data on its anti-cholesterol drug Repatha.
Can shares of Amgen rebound from todays selloff?
Yes, is the answer from RBC Capital Management analyst Michael Yee. He argues that the drug makers share price can grind back up if access to Repatha increases over the next few quarters. Earlier today, Amgen released data from an outcome study that missed expectations, leading some analyst to predict that health plans will continue to restrict access to the drug.
As Yee writes:
A number of key developments midday at the ACC conference that should shed increased confidence that Repatha reimbursement and utilization will continue to increase over time driving a new growth driver for AMGN and increased confidence in a new product cycle. If reimbursement does start to open up over next few quarters (tracking IMS scripts and other datapoints) and AMGN manages their execution on quarters/guidance – stock should recover off today’s overreaction reflecting high expectations
- [By Stavros Georgiadis]
Gilead Sciences (NSDQ:GILD) has underperformed the market with its stock price down almost 25% compared to a 10.33% gain in Nasdaq Composite (INDX:COMPX) and 14.60% gain of Dow Jones Industrial Average (INDX:INDU). Gilead and Amgen (NSDQ:AMGN)have had a very tough year, so it is interesting to know if now is the time to invest in GILD stock, not from a bottom fishing point of investing, which is often too risky, but on some solid financial and fundamentals arguments.
- [By Chris Lange]
Shares of Amgen Inc. (NASDAQ: AMGN) saw a handy gain to close out the week after the company won a Delaware court ruling that blocked Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) from selling their cholesterol-lowering drug in the United States. Essentially the court found that the drug Praluent actually infringed upon Amgens patents for its rival treatment Repatha.
Top 5 Low Price Stocks To Own Right Now: AirMedia Group Inc(AMCN)
- [By Paul Ausick]
AirMedia Group Inc. (NASDAQ: AMCN) posted a 52-week low of $1.04 after closing down 23% on Wednesday at $1.35. The 52-week high is $3.30. Volume was about 4 million, nearly 20 times the daily average of around 230,000 million shares. The Chinese outdoor advertising company said yesterday that it is terminating a potential go-private transaction.
Top 5 Low Price Stocks To Own Right Now: Real Goods Solar, Inc.(RGSE)
- [By Ashley Moore]
Here is a list of the top 10 best small-cap stocks based on price gains per share so far in 2017:
Company (Ticker)Price per Share% Change AquaBounty Technologies Inc. (Nasdaq: AQB)$14.338,646.99%Rennova Health Inc. (Nasdaq: RNVA)$3.133,333.73%China Gengsheng Minerals Inc. (OTCMKTS: CHGS)$0.021,718.18%Sunshine Heart Inc. (Nasdaq: SSH)$3.851,071.43%CTI BioPharma Corp. (Nasdaq: CTIC)$4.30991.76%Catalyst Biosciences Inc. (Nasdaq: CBIO)$6.22853.85%TearLab Corp. (Nasdaq: TEAR)$4.20707.85%Pulmatrix Inc. (Nasdaq: PULM)$3.86566.10%Real Goods Solar Inc. (Nasdaq: RGSE)$1.43498.75%Calithera Biosciences Inc. (Nasdaq: CALA)$11.70281.54%
- [By Lisa Levin]
Shares of Real Goods Solar, Inc. (NASDAQ: RGSE) got a boost, shooting up 15 percent to $1.26 after the company issued a business update. RGS Energy expects Q1 sales of $1.96 million, up from $670,000 in the fourth quarter.
- [By Peter Graham]
A long term performance chart shows Vivint Solar Holdings along with small cap solar installation stock Sunrun Inc (NASDAQ: RUN) below their IPO prices while Real Goods Solar, Inc (NASDAQ: RGSE)has imploded after being a highflyer:
- [By Lisa Levin]
Shares of Real Goods Solar, Inc. (NASDAQ: RGSE) got a boost, shooting up 22 percent to $2.98 after dropping 7.89 percent on Monday. RGS Energy disclosed that it has completed its $11.5 million public offering of common stock and warrants.
Top 5 Low Price Stocks To Own Right Now: Regeneron Pharmaceuticals, Inc.(REGN)
- [By Todd Campbell, Demitrios Kalogeropoulos, and Reuben Gregg Brewer]
In the case of these three stocks, however, it may be worth taking a gamble. Our contributors think catalysts at Regeneron Pharmaceuticals (NASDAQ:REGN), Royal Dutch Shell (NYSE:RDS-B), and United Parcel Service (NYSE:UPS) can get them back to their winning ways. Read on to find out if these down-and-out stocks are right for your portfolio.
- [By WWW.THESTREET.COM]
That’s why Cramer said he’ll be listening for news coming from Celgene (CEL) , Amgen (AMGN) , Allergan (AGN) , an Action Alerts PLUS holding, and Regenron (REGN) , all of which are set to present. Of the four, Cramer said he’s sticking with Allergan and Amgen.
- [By Ben Levisohn]
It hasn’t been an easy time for investors inRegeneron Pharmaceuticals (REGN) recently…and today’s price action is likely to reinforce the sense of whiplash they must be feeling.
Agence France-Presse/Getty Images
What do I mean? Regeneron’s dropped 14% during the last three months, the result of a patent suit with Amgen(AMGN) over its anti-cholesterol drug Praluent, which a judge had set it wouldn’t be able to sell in the U.S.Then last night, there was finally good news: Ajudge ordered a stay, which would allow Regeneron to sell Praluent, and resulted in a 2% pop in its shares last night after the market close. But then Regeneron reported earnings, and while profits of $3.04 cents a share metthe Street consensus, Regeneron missed on sales and offered disappointing guidance. That caused Regeneron shares to sink 2.1% in pre-open trading.
Fast forward to this afternoon, and and now they’re up nearly 3%. Credit Suisse analyst Alethia Young and team explain why the injunction outweighs the earnings:
Company issued Eylea guidance for 2017- they guided single digit
percentage growth over 2016. Consensus had been for 12% growth and we
had modeled 11% growth.
EPS for 4Q came in at $3.04 in line with $3.04 consensus. Since the company has already provided OpEx guidance for 2017 and the Eylea 4Q estimate ahead of today we think earnings are less of a focus.
We are curious where in the single digit percentage growth for Eylea the company means- 9% YoY growth wouldnt be too far from consensus vs. 3%
As we wrote last night, we would expect shares to trade up due to the injunction stay. We would expect shares to be up 2-4% from the injunction stay, but the effect might be muted somewhat by the Eylea guide. We would guess shares might be up 1 to 3% today.
Shares ofRegeneron Pharmaceuticals have gained 2.8% to $363.04 at 1:57 p.m. today, while the iS
Top 5 Low Price Stocks To Own Right Now: Interpublic Group of Companies, Inc. (The)(IPG)
- [By Paul Ausick]
The Interpublic Group of Companies Inc. (NYSE: IPG) dropped about 4% Wednesday to post a new 52-week low of $21.28 after closing Tuesday at $22.16. The 52-week high is $25.71. Volume reached nearly 10 million shares traded, more than double the daily average of around 3.8 million. Tuesday’s weak earnings report continued to weigh on the share price.
- [By Laurie Kulikowski]
Interpublic is our income play in our media universe. While other stocks we cover offer a higher yield than IPG’s 2.1%, the company’s double digit EPS growth projections for 2016 (following an estimated 18% in 2015) will also likely be a driver of outperformance for the year. While results can be somewhat volatile for IPG, we would point to record new business win backlog this year, which improves our conviction that the better than average recent organic revenue growth trends will continue next year. At 18x our 2016 EPS estimate, we find IPG shares attractive at current levels for another projected year of healthy double digit total returns.
- [By Paul Ausick]
The Interpublic Group of Companies Inc. (NYSE: IPG) dropped about 2.3% Thursday to post a new 52-week low of $20.94 after closing Wednesday at $21.44. The 52-week high is $25.71. Volume reached nearly 13 million shares traded, nearly 3 times the daily average of around 3.8 million. The company had no specific news, but Tuesday’s weak earnings report continues to weigh on the share price.
- [By Laurie Kulikowski]
Net operating cash flow has significantly increased by 59.42% to $280.90 million when compared to the same quarter last year. In addition, INTERPUBLIC GROUP OF COS has also vastly surpassed the industry average cash flow growth rate of 8.14%.